Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma. (September 2016)

• Record Type: Journal Article
• Authors: van der Steen-Banasik, E.; Christiaens, M.; Shash, E.; Coens, C.; Casado, A.; Herrera, F.G.; Ottevanger, P.B.
• Is Part Of: European journal of cancer. Volume 65(2016)
• Page Start: 172
• Page End: 181
• Publication Date: 2016-09
• Subjects: Genital neoplasms, female -- Uterine neoplasms -- Carcinoma, endometrioid -- Endometrial carcinoma -- Radiotherapy -- Brachytherapy -- Intracavity radiotherapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/j.ejca.2016.07.005
• Languages: English
• ISSNs: 0959-8049

Abstract

Abstract: Background and purpose: Radiotherapy is a good option for inoperable and frail patients diagnosed with endometrial cancer. Because of the lack of large multicentre trials, a systematic review was performed in an attempt to get an overview on the feasibility and efficacy of this specific approach. Materials and methods: We performed a bibliographic search for articles in English or French which were published in PubMed from the start of this database in January 1969 to identify publications on radiation therapy (RT) as single treatment for localised non-operable carcinoma of the endometrium. The review was completed following the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. Results: Twenty-five reports containing 2694 patients treated with RT as single treatment were identified that fulfilled the selection criteria. Disease-specific survival (DSS) at 5 years was reported for a cohort of 1322 (49.1%) patients. The combined DSS for this group of patients was 78.5% (range: 68.4–92%; 95% confidence interval: 74.5–82.5). External beam radiation therapy (EBRT) combined with brachytherapy (BT) was used in 1278 patients (47.4%), BT alone in 1383 patients (51.3%), and EBRT alone in 33 patients (1.2%). The average occurrence of grade III or worse late toxicity was 3.7% for EBRT + BT, 2.8% for BT alone, and 1.2% for EBRT alone. Conclusions: RT is in terms of disease control and toxicity, an acceptable option for non-surgical candidate patients. Prospective multicentre randomised or observational trials are needed to validate these results. Highlights: Data are heterogeneous due to a long selected period and single institution reports. Brachytherapy (BT) provides an essential contribution to primary endometrial cancer irradiation. External beam radiation therapy and/or BT irradiation for non-operable endometrial cancer is feasible. Modern radiation therapy technology decreases side-effects and provides precise target coverage. An international randomised or observational registration study is very desirable.